a Clinical Pharmacology and Toxicology Program , McGill University , Montreal , QC , Canada.
b Emergency Department , King Saud University , Riyadh , Saudi Arabia.
Clin Toxicol (Phila). 2018 Feb;56(2):81-89. doi: 10.1080/15563650.2017.1370096. Epub 2017 Sep 1.
Lamotrigine is a broad-spectrum anticonvulsant commonly used to treat seizure and bipolar mood disorders. Evidence from case series and retrospective studies indicate that lamotrigine overdose is usually benign. However, there are reported cases of cardiac arrest and mortality following lamotrigine overdose. We undertook a systematic review of the literature on lamotrigine overdoses to better understand the clinical severity, the relevance of serum concentrations, and therapeutic interventions for overdose.
To characterize manifestations of acute lamotrigine overdose, determine if serum concentrations predict poisoning severity, and evaluate the effectiveness of overdose management interventions.
We performed a literature search across eight databases, including Medline, EMBASE, and the Cochrane Library, from database inception to April 2014. Major bibliographic databases were updated on 31 May 2017. Articles were eligible if they described acute or acute on chronic lamotrigine overdose. At least one serum lamotrigine concentration had to be reported for inclusion. Reports on chronic poisoning, studies describing adverse effects of therapeutic use, and animal studies were excluded.
We retrieved 6238 records; 48 (51 cases) met the inclusion criteria. Cases primarily involved adults (70.6%). Potentially life-threatening symptoms of overdose included seizures (55%), Glasgow Coma Scale ≤8 (20%), hypotension (12%), and wide complex tachycardia (WCT) and cardiac arrest (6%). Among the 25 cases exposed to lamotrigine alone (13 adult; 12 pediatric), 2 adult fatalities occurred (4 g and 7.5 g ingested) and 8 pediatric cases experienced seizures (all children ≤3.5-years-old, 75% without an underlying seizure disorder, ≥ 525 mg ingested). The lowest seizure-associated serum concentration was 3.8 mg/L and 25.6 mg/L for pediatric and adult patients, respectively, suggesting children may be more susceptible to CNS toxicity. Cardiovascular toxicities occurred primarily in adult patients (threshold >25 mg/L). Overdose interventions included benzodiazepines (53%), propofol or barbiturates (14%), NaHCO (20%), lipid therapy (12%), and extracorporeal elimination (10%). NaHCO yielded no response in four of nine cases with conduction delays; however, two of the four cases subsequently responded with lipid therapy.
Most cases reporting lamotrigine exposures observed mild or no toxicity; however, large exposures were associated with severe CNS depression, seizures, cardiac conduction delays, wide complex tachycardia, and death. In adults with a serum concentration >25 mg/L, severe toxicity may occur. In patients ≤3.5 years of age, ingestions of ≥525 mg may produce severe CNS depression and seizures.
拉莫三嗪是一种广谱抗惊厥药,常用于治疗癫痫和双相情感障碍。来自病例系列和回顾性研究的证据表明,拉莫三嗪过量通常是良性的。然而,有报道称拉莫三嗪过量会导致心脏骤停和死亡。我们对拉莫三嗪过量的文献进行了系统评价,以更好地了解急性中毒的临床严重程度、血清浓度的相关性以及过量管理干预措施。
描述急性拉莫三嗪中毒的表现,确定血清浓度是否能预测中毒严重程度,并评估过量管理干预措施的效果。
我们在八个数据库(包括 Medline、EMBASE 和 Cochrane 图书馆)中进行了文献检索,检索时间从数据库建立到 2014 年 4 月。2017 年 5 月 31 日更新了主要的文献数据库。如果文章描述了急性或慢性拉莫三嗪中毒,就符合纳入标准。至少要有一份血清拉莫三嗪浓度报告才能纳入。排除慢性中毒报告、描述治疗使用不良反应的研究以及动物研究。
我们共检索到 6238 条记录;其中 48 篇(51 例)符合纳入标准。这些病例主要涉及成年人(70.6%)。与过量有关的潜在危及生命的症状包括癫痫发作(55%)、格拉斯哥昏迷量表评分≤8(20%)、低血压(12%)、宽复合性心动过速(WCT)和心脏骤停(6%)。在 25 例单独暴露于拉莫三嗪的病例中(13 例为成人;12 例为儿童),有 2 例成人死亡(分别摄入 4 克和 7.5 克),8 例儿童出现癫痫发作(所有儿童均≤3.5 岁,75%无潜在癫痫发作障碍,摄入量≥525 毫克)。与癫痫发作相关的最低血清浓度分别为儿童 3.8 毫克/升和成人 25.6 毫克/升,这表明儿童可能更容易受到中枢神经系统毒性的影响。心血管毒性主要发生在成年患者中(阈值>25 毫克/升)。过量干预措施包括苯二氮䓬类药物(53%)、丙泊酚或巴比妥类药物(14%)、碳酸氢钠(20%)、脂质治疗(12%)和体外清除(10%)。碳酸氢钠在 9 例出现传导延迟的病例中没有反应,但其中 4 例随后对脂质治疗有反应。
大多数报告拉莫三嗪暴露的病例观察到轻度或无毒性;然而,大剂量暴露与严重的中枢神经系统抑制、癫痫发作、心脏传导延迟、宽复合性心动过速和死亡有关。在血清浓度>25 毫克/升的成年患者中,可能会发生严重的毒性。在≤3.5 岁的儿童中,摄入≥525 毫克可能会导致严重的中枢神经系统抑制和癫痫发作。